Associate or Professor of Clinical Pediatircs-CHLA Section Head, Transplantation and Cellular T[...]

Associate or Professor of Clinical Pediatrics – CHLA Section Head, Transplantation and Cellular Therapy Endowed Chair The Cancer and Blood Disease Institute (CBDI) at the Children’s Hospital Los Angeles (CHLA) and the Division of Hematology‑Oncology within the Department of Pediatrics, Keck School of Medicine, University of Southern California (USC) are recruiting an internationally recognized leader to serve as Head of the Section of Transplantation and Cellular Therapy and Endowed Chair in Transplantation and Cellular Therapy. This individual will oversee clinical and research activities and program expansion in pediatric hematopoietic stem cell transplantation and cancer cell therapy. They will be expected to conduct research and further advance a leading research program that integrates laboratory and clinical science to develop and deliver innovative hematopoietic transplantation, gene, and cell therapies. The position includes membership at the USC Norris Comprehensive Cancer Center and an academic appointment through USC Keck School of Medicine at the level of Associate Professor or Professor, appropriate to training and experience. The CBDI’s Transplantation and Cellular Therapy Program currently performs approximately 80‑100 transplants annually for a wide variety of pediatric disorders including malignant, hematological, immunodeficiency and other genetic diseases, and approximately 20‑40 CAR T‑cell therapies each year. The Program has a cell processing laboratory and a cGMP facility and is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and the National Marrow Donor Program (NMDP). The CBDI is the largest and top‑ranked pediatric hematology‑oncology program in the western U.S. The U.S. News & World Report ranked the CBDI #7 and CHLA #5 in the nation in 2021‑2022. The CBDI has a large clinical trials operation that supports programs in hematology, oncology, and transplantation/cellular therapy. Three leading, international clinical trials consortia are headquartered within the CBDI: Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL); New Approaches to Neuroblastoma Therapy (NANT); and Children’s Hospital‑Acquired Thrombosis (CHAT). The CBDI is an active member of additional leading consortia including the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). CBDI investigators conduct extensive bench‑to‑bedside research. Research funding in FY20 totaled $59 million, with $17 million in new awards ($7.5M from NIH). The CBDI hosts an ACGME‑accredited pediatric hematology‑oncology fellowship training program and 1‑year advanced subspecialty fellowships in Transplantation/Cellular Therapy, Coagulation, Neuro‑Oncology, and AYA Oncology. Administrative and research support including staff, resources and infrastructure will be provided. CHLA and USC are equal‑opportunity, affirmative‑action employers. The division greatly values diversity and is committed to building a vibrant and culturally diverse community of faculty that best reflects the patients and families we serve. Individuals from underrepresented groups in medicine are especially encouraged to apply. For inquiries, please contact: Alan S. Wayne, M.D. Director, Cancer and Blood Disease Institute Head, Division of Hematology‑Oncology Vice Chair, Department of Pediatrics Children's Hospital Los Angeles Associate Director, USC Norris Comprehensive Cancer Center Professor of Pediatrics and Medicine Keck School of Medicine University of Southern California Alfred E. Mann Family Foundation Chair in Cancer Research View email address on click.appcast.io Women and men, and members of all racial and ethnic groups, people with disabilities, and veterans are encouraged to apply. The University of Southern California strongly values diversity and is committed to equal opportunity in employment. #J-18808-Ljbffr University of Southern California